Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Current Leases (2016 - 2026)

Ekso Bionics Holdings has reported Current Leases over the past 11 years, most recently at $441000.0 for Q4 2025.

  • On a quarterly basis, Current Leases rose 3.28% to $441000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $441000.0, a 3.28% increase, with the full-year FY2025 number at $441000.0, up 3.28% from a year prior.
  • Current Leases reached $441000.0 in Q4 2025 per EKSO's latest filing, down from $461000.0 in the prior quarter.
  • The five-year high for Current Leases was $547000.0 in Q1 2021, with the low at $51000.0 in Q2 2022.
  • The 5-year median for Current Leases is $372000.0 (2021), against an average of $362700.0.
  • Peak YoY movement for Current Leases: tumbled 90.08% in 2022, then skyrocketed 601.96% in 2023.
  • Tracing EKSO's Current Leases over 5 years: stood at $229000.0 in 2021, then soared by 48.91% to $341000.0 in 2022, then rose by 6.45% to $363000.0 in 2023, then increased by 17.63% to $427000.0 in 2024, then rose by 3.28% to $441000.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $441000.0, $461000.0, and $448000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.